NASALCART™ · RESEARCH USE ONLY
A tri-layer human nasal-tissue construct — epithelium, stroma and cartilage — with every layer linked to a release criterion, a biological identity check or a downstream decision readout.
THE PROBLEM
01
Epithelial models are strong for transport and cilia, but can miss deeper stromal and cartilage injury.
02
Cartilage and matrix response matter to local tolerability, yet are rarely standardized in routine screens.
03
Every new comparison becomes a bespoke study, so results never line up across programs.
THE PAID QUESTION
“Which formulation and device combination creates the lowest local human-tissue injury signal — and deserves to advance?”
THE CONSTRUCT
Locked, version-controlled design with defined dimensional tolerance and repeatable handling.
A target mechanical window benchmarked against published comparators.
Tracked at 24 hours, 72 hours and day 7 against pre-specified thresholds.
Layer retention, morphology and interface continuity across all three layers.
Cartilage identity confirmed and monitored for fibrotic or hypertrophic drift.
Every construct tied to its lot, cell source, run record and QC history.
ASSAY STACK
Each readout is interpreted against untreated, vehicle, non-damaging and damaging controls — so a signal means something before it reaches your program team.
Viability and cytotoxicity
24 h · 72 h · 7 d
Response versus negative and positive controls
IL-6 · IL-8 · TNF-α
Phenotype retention
SOX9 · ACAN · COL2A1
Fibrotic and hypertrophic drift
COL1A1 · COL10A1
Matrix formation and retention
GAG · histochemical staining
Catabolic injury response
MMP-13 · ADAMTS5
Epithelial barrier metrics are added where the construct format supports a validated barrier measurement.
HOW A PILOT WORKS
01 · INPUT
Formulation, dose, excipient, concentration, device and exposure pattern.
02 · EXPOSE
Standardized acute or repeat-exposure protocol on a lot-controlled construct.
03 · READ OUT
Barrier, inflammation, cartilage phenotype and matrix degradation.
04 · COMPARE
Candidates scored against pre-specified controls and acceptance logic.
05 · DECIDE
Rank, reformulate, advance, escalate — or stop.
WHAT A PILOT LETS YOU DECIDE
| Your question | Evidence delivered | Decision it supports |
|---|---|---|
| Which lead formulation should advance? | Comparative, control-referenced response profile | Rank candidates and select a lead |
| Is an excipient or concentration driving injury? | Component or dose comparison | Reformulate or reduce concentration |
| Does repeat exposure amplify injury? | Acute versus repeated exposure response | Alter the schedule or stop |
| Do we need an epithelial or in vivo study? | Tissue-response signal with stated limitations | Escalate to the next fit-for-purpose model |
THE DECISION PACKET
The packet sharpens your next experiment and makes uncertainty visible. It does not certify clinical safety.
WHO IT'S FOR
Formulation and CMC, translational sciences, preclinical safety and innovation groups at pharma and biotech companies — and CROs building sponsor-facing study packages.
ROADMAP
NOW
Tri-layer epithelium, stroma and cartilage with a documented QC standard.
NEXT
Mature air-liquid interface features and advanced barrier readouts.
EXPAND
Donor variants, device-specific protocols, nose-to-brain interfaces.
COMPOUND
Versioned benchmarks and cross-program response signatures.
LIVE INTERACTIVE SIMULATION
Step through all six platform stages, adjust dose, barrier and targeting, and see how each delivery route resolves. Illustrative design indices, not experimental data.
Bring 2–5 candidate formulations or device conditions and one local-tissue question.